Treatment News : African Study Bolsters Argument to Begin HIV Therapy Early

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » November 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

November 9, 2012

African Study Bolsters Argument to Begin HIV Therapy Early

While many current international guidelines advise beginning antiretroviral (ARV) therapy when CD4 counts are in the 200 to 350 range, a new African study has shown that there is significantly higher risk of death for those who start therapy with a CD4 count below 500, aidsmap reports. Published in BMC Infectious Diseases, the randomized controlled trial followed 3,295 serodiscordant couples enrolled in the Partners in Prevention study in Africa, in 14 sites across seven sub-Saharan African countries, for up to two years. All HIV-positive participants began with a CD4 count of 250 or higher and were given ARV treatment according to local protocol.

The researchers saw 109 deaths from any cause, including 74 deaths in HIV-positive participants and 25 among negative people. By comparing HIV-positive mortality rates to the seronegative cohort, the scientists found that the lower the CD4 counts and the higher the viral load, the more likely HIV-positive participants were to die.  Specifically, having a CD4 count of 250 to 349 led to an excess mortality of 15.2 deaths per 1,000 patient years, while CD4 counts between 350 and 499 had a rate of 8.9 deaths. Most notably, those with CD4 counts at or above 500 had the same mortality rates as their HIV-negative counterparts.

Even though the U.S. Department of Health and Human Services changed its guidelines in March 2012 to recommend treatment initiation when CD4 levels drop below 500 (since 2009, the recommendation had been to start while in the range of 350 to 500), the advice still has its dissenters. This study’s authors posit that their findings argue a strong clinical benefit for the newer standard of care.

To read the aidsmap report, click here.

To read an abstract of the study and find a link to the full PDF, click here.

Search: HIV, AIDS, Africa, early, treatment, aidsmap, CD4 count, BMC Infectious Diseases, serodiscordant, death, mortality, treatment guidelines.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adoniz89
    san dimas
    California


    zeze42
    Bay Area - Peninsula
    California


    ernienyc
    Bronx
    New York


    josebos
    Boston strong
    Massachusetts
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.